Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 14/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23329393 | 0.76 | CD38 (0.47) | CD38GRIN2B | |
| SCHEMBL23329867 | 0.73 | CD38 (0.52) | CD38 | |
| SCHEMBL23329531 | 0.72 | HDAC4 (0.42) | CD38 | |
| SCHEMBL23329175 | 0.67 | CD38 (0.51) | CD38DYRK1A | |
| SCHEMBL27890308 | 0.64 | CD38 (0.44) | CD38MAPTDYRK1A | |
| SCHEMBL4541085 | 0.62 | CD38 (0.49) | CD38MAPTDYRK1AKDM4E | |
| SCHEMBL20680372 | 0.62 | CD38 (0.59) | CD38ACLY | |
| SCHEMBL22010018 | 0.60 | MAPT (0.45) | CD38MAPTDYRK1A | |
| SCHEMBL13745367 | 0.60 | DYRK1A (0.46) | CD38MAPTDYRK1A | |
| SCHEMBL23185433 | 0.59 | WNT1 (0.44) | CD38MAPTDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021087087-A1 | N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS | MITOBRIDGE INC. (US) | 2021-05-06 | — | — | WO | disclosed |